ADC Therapeutics SA
| NYSE: ADCT | Healthcare / Biotechnology / Switzerland |
| 1.07 | 0 | 0.00 | Vol 269.89K | 1Y Perf -62.72% |
| Dec 7th, 2023 16:00 DELAYED |
| BID | 0.9700 | ASK | 1.11 | ||
| Open | 1.06 | Previous Close | 1.07 | ||
| Pre-Market | - | After-Market | - | ||
| - -% | - - |
| Target Price | 13.71 | Analyst Rating | Moderate Buy 2.14 | |
| Potential % | 1.18K | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | ★+ 43.25 | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | ★ 39.34 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Price Range Ratio 52W % | 13.17 | Earnings Rating | — | |
| Market Cap | 86.29M | Earnings Date | 7th Nov 2023 | |
| Alpha | -0.08 | Standard Deviation | 0.19 | |
| Beta | 1.24 |
Today's Price Range 1.031.13 | 52W Range 0.35995.75 |
Summary:
Neutral
| Technical Indicators: | Neutral |
| Moving Averages: | Buy |
| Performance | |||
|---|---|---|---|
| 1 Week | -3.60% | ||
| 1 Month | 78.33% | ||
| 3 Months | 0.00% | ||
| 6 Months | -57.20% | ||
| 1 Year | -62.72% | ||
| 3 Years | -97.00% | ||
| 5 Years | - | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -59.99 | |||
ROE last 12 Months | -113.68 | |||
ROA (5Y Avg) | -22.72 | |||
ROA last 12 Months | -28.39 | |||
ROC (5Y Avg) | -50.55 | |||
ROC last 12 Months | -58.26 | |||
Return on invested Capital Q | -18.03 | |||
Return on invested Capital Y | -10.29 | |||
Assets Turnover | 0.10 | |||
Receivables Turnover | 3.90 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -1.60 | ||||
| 2.63 | ||||
| 2.01 | ||||
| - | ||||
| -3.20 | ||||
| -1.89 | ||||
| 3.06 | ||||
| 1.35 | ||||
| 11.44M | ||||
| Forward PE | - | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 4.60 | ||||
| 5.00 | ||||
| 0.50 | ||||
| 1.11 | ||||
| -3.90 | ||||
| Leverage Ratio | 4.30 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 96.90 | ||||
| -96.70 | ||||
| -95.10 | ||||
| - | ||||
| -93.96 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 140.11M | ||||
| 1.80 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q03 2023 | -0.61 | -0.58 | 4.92 |
| Q02 2023 | -0.44 | -0.58 | -31.82 |
| Q01 2023 | -0.80 | -0.74 | 7.50 |
| Q04 2022 | -0.49 | -0.30 | 38.78 |
| Q03 2022 | -0.51 | -0.65 | -27.45 |
| Q02 2022 | -0.96 | -0.84 | 12.50 |
| Q01 2022 | -0.76 | -0.22 | 71.05 |
| Q04 2021 | -0.87 | -0.45 | 48.28 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Next Report Date | - |
| Estimated EPS Next Report | -0.61 |
| Estimates Count | 5 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 269.89K |
| Shares Outstanding | 80.64K |
| Shares Float | 54.60M |
| Trades Count | 1.19K |
| Dollar Volume | 290.28K |
| Avg. Volume | 501.98K |
| Avg. Weekly Volume | 741.04K |
| Avg. Monthly Volume | 438.64K |
| Avg. Quarterly Volume | 326.24K |
ADC Therapeutics SA (NYSE: ADCT) stock closed at 1.07 per share at the end of the most recent trading day (a 0% change compared to the prior day closing price) with a volume of 269.89K shares and market capitalization of 86.29M. Is a component of indices and it is traded on NYSE exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 138 people. ADC Therapeutics SA CEO is .
The one-year performance of ADC Therapeutics SA stock is -62.72%, while year-to-date (YTD) performance is -72.14%. ADCT stock has a five-year performance of %. Its 52-week range is between 0.359908 and 5.75, which gives ADCT stock a 52-week price range ratio of 13.17%
ADC Therapeutics SA currently has a PE ratio of -1.60, a price-to-book (PB) ratio of 2.63, a price-to-sale (PS) ratio of 2.01, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -28.39%, a ROC of -58.26% and a ROE of -113.68%. The company’s profit margin is -93.96%, its EBITDA margin is -95.10%, and its revenue ttm is $140.11 Million , which makes it $1.80 revenue per share.
Of the last four earnings reports from ADC Therapeutics SA, there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.61 for the next earnings report. ADC Therapeutics SA’s next earnings report date is -.
The consensus rating of Wall Street analysts for ADC Therapeutics SA is Moderate Buy (2.14), with a target price of $13.71, which is +1 181.31% compared to the current price. The earnings rating for ADC Therapeutics SA stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
ADC Therapeutics SA has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
ADC Therapeutics SA has a Neutral technical analysis rating based on Technical Indicators (ADX : 22.15, ATR14 : 0.11, CCI20 : 133.08, Chaikin Money Flow : -0.03, MACD : 0.09, Money Flow Index : 89.35, ROC : 50.64, RSI : 67.89, STOCH (14,3) : 80.57, STOCH RSI : 0.69, UO : 61.04, Williams %R : -19.43), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of ADC Therapeutics SA in the last 12-months were:
ADC Therapeutics SA
ADC Therapeutics SA is a United States-based clinical-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ADCT-402, ADCT-301, ADCT-602, and ADCT-601.
CEO:
Telephone: +41 216530200
Address: Route de la Corniche 3B, Epalinges 1066, , CH
Number of employees: 138
